Stockscreener 앱 받기
28.35
0.43%
0.12
전일 마감가:
$28.23
열려 있는:
$28.38
하루 거래량:
55,493
Relative Volume:
0.51
시가총액:
$141.71M
수익:
$34.77M
순이익/손실:
$-74.04M
주가수익비율:
-3.5368
EPS:
-8.0157
순현금흐름:
$-79.76M
1주 성능:
+2.07%
1개월 성능:
+219.62%
6개월 성능:
+212.31%
1년 성능:
-50.70%
1일 변동 폭
$28.11
$28.70
1주일 범위
$27.80
$28.70
52주 변동 폭
$5.21
$57.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
MRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
28.35 | 141.11M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | William Blair | Outperform |
| 2024-11-15 | 재개 | Citigroup | Buy |
| 2024-03-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc.MRSN - PR Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-SMLR, MRSN, CDTX, and RYI - The Malaysian Reserve
Day One Biopharmaceuticals Expands with Mersana Acquisition - StocksToTrade
Is Mersana Therapeutics Inc 0M4 a good long term investmentLarge Cap Stability Picks & High Return Trading Ideas - earlytimes.in
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI - Sahm
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Is Mersana Therapeutics Inc. (0M4) stock prepared for digital transitionRate Hike & Daily Growth Stock Investment Tips - Newser
Can Mersana Therapeutics Inc. (0M4) stock stage a strong rebound this quarter - Newser
Can Mersana Therapeutics Inc. (0M4) stock sustain breakout momentumJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - Newser
Why Mersana Therapeutics Inc. (0M4) stock could be next leaderJuly 2025 Opening Moves & Community Consensus Stock Picks - Newser
How Mersana Therapeutics Inc. (0M4) stock compares with top peersQuarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser
Will Mersana Therapeutics Inc. (0M4) stock attract long term capital inflowsJuly 2025 Review & Consistent Income Trade Ideas - Newser
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Will Mersana Therapeutics Inc. (0M4) stock deliver compounding returnsQuarterly Trade Report & Breakout Confirmation Alerts - Newser
Options Flow: How Mersana Therapeutics Inc. (0M4) stock compares with market leadersJuly 2025 Setups & Daily Technical Forecast Reports - moha.gov.vn
How Mersana’s Acquisition Is Changing the Story and Analyst Outlook for Investors - Yahoo Finance
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights - Sahm
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerEXAS, SEE, CDTX, and MRSN - The Malaysian Reserve
Halper Sadeh LLC Encourages SEE, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Is Mersana Therapeutics Inc. (0M4) stock a buy before new product rolloutJuly 2025 Rallies & Risk Controlled Daily Plans - moha.gov.vn
ENN Energy Holdings Announces Conditional Privatization Proposal - The Globe and Mail
683 Capital Management, LLC Increases Stake in Mersana Therapeutics Inc. - GuruFocus
Can Mersana Therapeutics Inc. (0M4) stock test all time highsJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
Will Mersana Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 Trade Ideas & Safe Capital Growth Stock Tips - newser.com
Is Mersana Therapeutics Inc. (0M4) stock testing key supportEarnings Risk Report & AI Driven Stock Reports - newser.com
Does Mersana Therapeutics Inc. qualify in momentum factor screeningShort Setup & Low Drawdown Momentum Ideas - newser.com
Why Mersana Therapeutics Inc. stock remains a top recommendationEarnings Miss & Free Reliable Trade Execution Plans - newser.com
Earnings visualization tools for Mersana Therapeutics Inc.2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Will Mersana Therapeutics Inc. stock benefit from infrastructure spending2025 Analyst Calls & Safe Entry Point Alerts - newser.com
How Mersana Therapeutics Inc. (0M4) stock reacts to weak economyTrade Exit Summary & Safe Capital Growth Tips - newser.com
Detecting price anomalies in Mersana Therapeutics Inc. with AIWeekly Trade Report & Low Risk Entry Point Guides - newser.com
Using data filters to optimize entry into Mersana Therapeutics Inc.Weekly Investment Summary & Low Risk Entry Point Guides - newser.com
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):